A Phase 4 interventional study of Epoetin alfa 450 IU/kg once a week and Epoetin alfa 150 IU/kg 3 times a week in Anemia and Neoplasms, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-05.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 7th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2006, is one of 20 in phase 4, and was the 107th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
77 studies in Anemia by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 74 finished, 9 (12%) have results posted.
Among the 77 studies in Anemia by Johnson & Johnson, this one is the 7th largest by enrollment of the 62 interventional ones that give a count, is one of 9 that started in 2006, is one of 5 in phase 4, and was the 74th registered.
Johnson & Johnson’s Anemia studies by the year they started, since 1988.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 77 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety of epoetin alfa in patients with cancer who have chemotherapy-related anemia.
Epoetin alfa is an agent similar to a hormone produced in the kidney (ie, erythropoietin) that functions to increase the amount of red blood cells made in the bone marrow. This is a randomized (study drug assigned by chance), open-label (patients and their doctors will know the identity of study drug administered), safety study of 2 dosing regimens (doses and schedules) of epoetin alfa administered to patients with cancer who have chemotherapy-related anemia. Anemia is a lack of red blood cells that can result in symptoms of weakness, shortness of breath, fatigue, tiredness, and decreased activity. The primary outcome measure in the study is the number of patients in each treatment group with at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) reviewed by an independent adjudication committee from Day 1 (baseline or the day of the first dose) through Week 16. An external review of relevant clinical data and medical imaging studies by an Adjudication Committee will be performed in a blinded fashion for confirmation of TVEs. The Adjudication Committee will confirm TVEs by reviewing all images (X-ray, Computed tomography [CT] scan, ultrasound, Magnetic Resonance Imaging [MRI] scan, etc) and other diagnostic procedures auch as coagulation tests or electrocardiograms in combination with a clinical patient profile as described for each specific type of TVE. Only TVEs that are determined by the Adjudication Committee to be clinically relevant and objectively confirmed will be counted in the analysis for the primary endpoint. Approximately 500 patients, who have cancer, are receiving chemotherapy, and are anemic, will take part in the study. Patients will participate in the study for up to 32 weeks (this includes a 2-week screening period to determine eligibility for the study, a 26-week treatment period, and a 4-week follow-up period to have end-of-study assessments [tests] performed). The length of participation in the study depends on the length of time the patient is receiving chemotherapy and epoetin alfa; patients in the study may receive up to a maximum of 26 weeks of treatment with epoetin alfa. Patients will be randomly assigned (assigned by chance like flipping a coin) to 1 of 2 treatment groups (Epoetin Alfa QW or Epoetin Alfa TIW). Patients assigned to the Epoetin Alfa QW Group will receive epoetin alfa at an initial dosage of 450 IU/kg once a week and patients assigned to Epoetin Alfa TIW Group will receive epoetin alfa 150 IU/kg 3 times a week by subcutaneous (underneath the skin) injection. Injections will be given preferably on Monday for patients in the Epoetin Alfa QW Group and on Mondays, Wednesdays, and Fridays for patients in the Epoetin Alfa TIW Group. During the study, patients will visit the study center weekly to have a blood sample collected to measure the amount of hemoglobin (red blood cells) in the blood. Depending on the hemoglobin level, the dose of epoetin alfa may be increased or decreased. Regardless of treatment group, if anemia does not improve in patients after 4 weeks of treatment, the dose of epoetin alfa will be increased to 300 IU/kg 3 times a week. If anemia does not improve after 4 weeks at the increased dose level of epoetin alfa (300 IU/kg 3 times a week), treatment with epoetin alfa will be stopped. In addition, during the study, patients may also receive treatment with iron supplements if the level of iron in the blood is low. During the study, safety will be monitored by evaluating adverse events and findings from clinical laboratory tests, 12-lead electrocardiograms (ECGs), blood pressure measurements, and physical examinations. Patients will receive epoetin alfa at an initial dose of 450 IU/kg once a week or 150 IU/kg 3 times a week by subcutaneous injection, preferably in the abdomen, for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks. Injections for Epoetin Alfa QW Group will be at the study center and for Epoetin TIW Group, the 1st weekly injection will be at the study center and the 2nd and 3rd weekly injections will be at the study center or at home by self-administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
Drug: Epoetin alfa 450 IU/kg once a week · Drug: Epoetin alfa 450 IU/kg once a week (QW)
Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Drug: Epoetin alfa 150 IU/kg 3 times a week · Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)
Drug page: Epoetin Alfa
450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Drug page: Epoetin Alfa
150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Drug page: Epoetin Alfa
450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
Drug page: Epoetin Alfa
150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16
Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.
Time frame: from randomization through Week 16
Number of Positively Adjudicated Thrombovascular Events
The number of participants who have at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) during the study.
Time frame: during the study (randomization through week 26)
Time to First Positively Adjudicated Thrombovascular Event
Analysis of time to first positively adjudicated thrombovascular event (TVE) measured from the date of randomization to the date of the first clinically relevant and objectively confirmed TVE as determined by the Adjudication Committee. Median time is non-estimable because of too few events, incidence was reported instead.
Time frame: during the study (randomization through week 26)
Number of Suspected Thrombovascular Events
Number of participants who have at least 1 suspected thrombovascular events (TVEs) during the entire study. Suspected TVEs were defined as suspected TVEs during the entire study, whether clinically relevant and objectively confirmed by the Adjudication Committee or not, whether confirmed by the investigator or not.
Time frame: during the study (randomization through week 26)
Time to First Suspected Thrombovascular Event
Analysis of time to first suspected thrombovascular event (TVE) measured from the date of randomization to the date of the first suspected TVE during the study. Median time is non-estimable because of too few events, incidence was reported instead.
Time frame: during the study (randomization through week 26)
Mortality
Number of participants who died during the study.
Time frame: during the study (randomization through week 26)
Number of Hemoglobin Responders
Hemoglobin response was defined as a hemoglobin increase of ≥2 g/dL from baseline or reaching a hemoglobin concentration of 12 g/dL, regardless of dose adjustment.
Time frame: during the study (randomization through week 26)
Red Blood Cell Transfusions
The number of participants who received at least 1 red blood cell (RBC) transfusion (packed RBC or whole blood) during the study.
Time frame: during the study (randomization through week 26)
This is a randomized, open-label, multicenter study evaluating thrombovascular events in participants with cancer receiving chemotherapy and administered Epoetin Alfa once weekly (QW) or three times a week (TIW) for the treatment of anemia.
| Milestone | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Started | 242 | 262 |
| Completed | 183 | 190 |
| Not completed | 59 | 72 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Lack of efficacy | 5 | 7 |
| Withdrew: Lost to follow-up | 6 | 8 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 20 | 17 |
| Withdrew: Chemotherapy termination | 10 | 15 |
| Withdrew: Disease progression | 7 | 7 |
| Withdrew: Prematurely termination of trial | 9 | 10 |
Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.
| particpants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16 | 5 | 10 |
The number of participants who have at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) during the study.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Number of Positively Adjudicated Thrombovascular Events | 5 | 13 |
Analysis of time to first positively adjudicated thrombovascular event (TVE) measured from the date of randomization to the date of the first clinically relevant and objectively confirmed TVE as determined by the Adjudication Committee. Median time is non-estimable because of too few events, incidence was reported instead.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Time to First Positively Adjudicated Thrombovascular Event | 5 | 13 |
Number of participants who have at least 1 suspected thrombovascular events (TVEs) during the entire study. Suspected TVEs were defined as suspected TVEs during the entire study, whether clinically relevant and objectively confirmed by the Adjudication Committee or not, whether confirmed by the investigator or not.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Number of Suspected Thrombovascular Events | 9 | 20 |
Analysis of time to first suspected thrombovascular event (TVE) measured from the date of randomization to the date of the first suspected TVE during the study. Median time is non-estimable because of too few events, incidence was reported instead.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Time to First Suspected Thrombovascular Event | 9 | 20 |
Number of participants who died during the study.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Mortality | 25 | 26 |
Hemoglobin response was defined as a hemoglobin increase of ≥2 g/dL from baseline or reaching a hemoglobin concentration of 12 g/dL, regardless of dose adjustment.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Number of Hemoglobin Responders | 179 | 187 |
The number of participants who received at least 1 red blood cell (RBC) transfusion (packed RBC or whole blood) during the study.
| participants | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Red Blood Cell Transfusions | 38 | 42 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Alfa QW | — | 53/242 (21.9%) | 157/242 (64.9%) |
| Epoetin Alfa TIW | — | 64/262 (24.4%) | 151/262 (57.6%) |
| Event | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/242 | 20/262 |
| PneumoniaInfections and infestations | 2/242 | 9/262 |
| AnaemiaBlood and lymphatic system disorders | 4/242 | 2/262 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/242 | 0/262 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/242 | 4/262 |
| Deep vein thrombosisVascular disorders | 3/242 | 4/262 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/242 | 4/262 |
| LeukopeniaBlood and lymphatic system disorders | 3/242 | 1/262 |
| NeutropeniaBlood and lymphatic system disorders | 2/242 | 3/262 |
| PancytopeniaBlood and lymphatic system disorders | 2/242 | 1/262 |
| Event | Epoetin Alfa QW | Epoetin Alfa TIW |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 81/242 | 72/262 |
| ThrombocytopeniaBlood and lymphatic system disorders | 52/242 | 54/262 |
| LeukopeniaBlood and lymphatic system disorders | 51/242 | 44/262 |
| NauseaGastrointestinal disorders | 27/242 | 40/262 |
| DiarrhoeaGastrointestinal disorders | 26/242 | 10/262 |
| VomitingGastrointestinal disorders | 13/242 | 24/262 |
| AstheniaGeneral disorders | 21/242 | 14/262 |
| FatigueGeneral disorders | 17/242 | 16/262 |
| PyrexiaGeneral disorders | 15/242 | 18/262 |
| AnorexiaMetabolism and nutrition disorders | 13/242 | 11/262 |
| Age, Categorical(Participants) | Epoetin Alfa QW | Epoetin Alfa TIW | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 160 | 173 | 333 |
| >=65 years | 81 | 88 | 169 |
| Age Continuous(years) | Epoetin Alfa QW | Epoetin Alfa TIW | Total |
|---|---|---|---|
| Mean | 58.8 ± 13.35 | 57.5 ± 13.53 | 58.1 ± 13.44 |
| Sex: Female, Male(Participants) | Epoetin Alfa QW | Epoetin Alfa TIW | Total |
|---|---|---|---|
| Female | 156 | 181 | 337 |
| Male | 86 | 81 | 167 |
| Region of Enrollment(participants) | Epoetin Alfa QW | Epoetin Alfa TIW | Total |
|---|---|---|---|
| Bulgaria | 6 | 7 | 13 |
| France | 7 | 6 | 13 |
| Germany | 51 | 55 | 106 |
| Great Britain | 1 | 4 | 5 |
| Greece | 8 | 12 | 20 |
| Italy | 13 | 13 | 26 |
| Poland | 7 | 6 | 13 |
| Romania | 21 | 20 | 41 |
| Russia | 88 | 93 | 181 |
| Slovakia | 9 | 11 | 20 |
| Ukraine | 31 | 35 | 66 |
No study locations are listed for this record.
The record gives a start of Jan 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →